Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I got my product yesterday, rolled some on and played 27 holes and it seemed to really help this 60 year old body!!
Become an examiner .Tiger Woods launches Twitter campaign for Fuse Science (video)
Add a comment Emily Kay, Golf Examiner
January 2, 2012 - Like this? Subscribe to get instant updates.
.0 0 0 0Submit0redditPrintEmail
StumbleUponredditPrintEmail.If you know how many times Tiger Woods has been the PGA Tour’s Player of the Year* and the number of professional wins he’s tallied** (answers below), you’re almost halfway to earning an “unbeatable” rating on the Tiger trivia section of Fuse Science’s new website.
@TigerWoods, who in November added the sports-nutrition company to his growing list of post-scandal endorsers, tweeted last week about the debut of the firm’s new online presence. The 17-time major champ (not one of the trivia queries) who turned 36 on December 30, is one of the four superstar jocks to headline the “athletes” page of the “Powered by Fuse” site.
There you’ll learn, among other factoids, that the world’s 23rd-ranked golfer has his own “Official Tiger Woods Channel” on YouTube. A quick tour of the Woods collection found that a compendium of the former ace’s Greatest Shots (2005-2009), with more than 184,700 views, was the most popular video in the assemblage.
Advertisement
As for poweredbyfuse.com, Woods shares the banner with NFL playoff-bound Houston Texans running back Arian Foster, Boston Red Sox slugger David Ortiz, and Tampa Bay Buccaneer cornerback Ronde Barber. Ortiz, by the way, took to the Twitterverse last week as well, with a trivia contest of his own that featured his fellow pitchmen.
“What do @TigerWoods @ArianFoster and I all have in common?” @davidortiz tweeted on December 30 -- clearly the launch day for the Fuse Science site. When one of his 192,000 followers guessed that the three heavyweights blew the candles out on the same day, Ortiz set the record straight.
“Nope, only Tiger's birthday today,” typed the BoSox designated hitter, who took time out from his off-season golf tourney and pre-spring training prep to shill for his backer. “Me @ArianFoster and @TigerWoods are all #PoweredByFuse and now you can be too”
Answers to trivia questions:
* 10
** 98
.
A Become an examiner .Tiger Woods launches Twitter campaign for Fuse Science (video)
Add a comment Emily Kay, Golf Examiner
January 2, 2012 - Like this? Subscribe to get instant updates.
.0 0 0 0Submit0redditPrintEmail
StumbleUponredditPrintEmail.If you know how many times Tiger Woods has been the PGA Tour’s Player of the Year* and the number of professional wins he’s tallied** (answers below), you’re almost halfway to earning an “unbeatable” rating on the Tiger trivia section of Fuse Science’s new website.
@TigerWoods, who in November added the sports-nutrition company to his growing list of post-scandal endorsers, tweeted last week about the debut of the firm’s new online presence. The 17-time major champ (not one of the trivia queries) who turned 36 on December 30, is one of the four superstar jocks to headline the “athletes” page of the “Powered by Fuse” site.
There you’ll learn, among other factoids, that the world’s 23rd-ranked golfer has his own “Official Tiger Woods Channel” on YouTube. A quick tour of the Woods collection found that a compendium of the former ace’s Greatest Shots (2005-2009), with more than 184,700 views, was the most popular video in the assemblage.
Advertisement
As for poweredbyfuse.com, Woods shares the banner with NFL playoff-bound Houston Texans running back Arian Foster, Boston Red Sox slugger David Ortiz, and Tampa Bay Buccaneer cornerback Ronde Barber. Ortiz, by the way, took to the Twitterverse last week as well, with a trivia contest of his own that featured his fellow pitchmen.
“What do @TigerWoods @ArianFoster and I all have in common?” @davidortiz tweeted on December 30 -- clearly the launch day for the Fuse Science site. When one of his 192,000 followers guessed that the three heavyweights blew the candles out on the same day, Ortiz set the record straight.
“Nope, only Tiger's birthday today,” typed the BoSox designated hitter, who took time out from his off-season golf tourney and pre-spring training prep to shill for his backer. “Me @ArianFoster and @TigerWoods are all #PoweredByFuse and now you can be too”
Answers to trivia questions:
* 10
** 98
.
A
Got mine!! order#1112
30k up and only one post???
Thanks burnshorty, it has been a long time here, maybe we will finally get some results with our investments in this company. something is up for sure, have a good one.
.0094 here
Yes Sir it sure has about 3yrs now that I see you here am buying tomorrow whats your opinion here.
HI burn
I sent mine to lmf this AM. eom
Somethings up, that's for sure!
Great find clrmng!!!
wow.....World Bulk Paclitaxel Market to Reach 1,040 Kilograms by 2012, According to New Report by Global Industry Analysts
Leading global and regional players operating in the industry include Abraxis BioScience Inc, Bioxel Pharma Inc, Bristol-Myers Squibb Co, Indena SpA, Hospira Inc, Teva Pharmaceuticals USA Inc, IVAX Corporation, Bedford Laboratories, and Xechem International Inc.
Lots of buys going through right now , whats up??????
New guidelines launched on sickle cell treatment
Wednesday 9th July 2008
England's first-ever guidelines for adult sickle cell care were launched today (Wednesday 9 July) by the Sickle Cell Society.
The standards include detailed guidelines on primary care, specialist networks for hospitals and clinics, management of chronic and acute conditions, blood transfusions, and screening.
Dr Allison Streetly, Programme Director for the Sickle Cell and Thalassaemia Screening Programme, said: "The introduction of these much-needed national guidelines on caring for adults with the disease is greatly welcome.
Together with the care standards for thalassaemia, they lay the foundation for a care framework where patient needs are properly understood both close to where people live and in specialist centres.
"An important next challenge will be to improve understanding of sickle cell and thalassaemia in schools, the workplace and in everyday lives, as well as among nurses and doctors. These standards will underpin education and deliver the funding where it is needed in future."
Sickle cell is one of the most commonly inherited genetic diseases in England. Around 240,000 people carry the gene with 12,500 people living with the disease, making it as common as cystic fibrosis. Events will be taking place across the country during July, run by local sickle cell care centres and support groups.
The announcement of the new guidelines coincides with Sickle Cell Awareness Month, with activities across the country running throughout July to promote the guidelines and improve awareness and management of sickle cell disease.
Sickle Cell Society
Take part in the MiP online risk management survey for practice managers
Your comments: (Terms and conditions apply)
"I think practices should raise more awareness of the disease. I personally have benefited from the awareness programmes" – Neri, Nigeria
Feedback
Should practices raise more awareness of sickle cell disease?
Name:
Email:
Location:
We welcome all feedback. However, we cannot publish anonymous comments, so please supply your name and location. Your details will not be displayed if you so request. To protect privacy we never publish email addresses.
Poor sickle cell treatment in Britain causing patient deaths
Thu 19 June 2008
An official report on the treatment of Sickle cell sufferers published by Neville Clare PhD, chair of the campaign group Sickle Watch has revealed Africans in Britain are subjected to poor treatment, overdosing with opioids all leading to avoidable deaths
A review of deaths nationally from sickle cell disorder and thalassaemia over two years has produced devastating findings:
- In nearly half of the cases examined, “the actual cause of death was debatable or unknown”.
- “Patients who were acutely ill were not offered support from sufficiently experienced medical staff”.
- “There is a need to monitor patients on opioids more carefully.”
- “Simple measures might well have avoided some of these deaths”.
The report describes the findings as “a wake-up call”. It recommends better ongoing care of all patients, and better management of those in acute pain. This should include monitoring of fluid intake, regular clinical review by a higher level of specialist expertise, and much better nursing observations including respiratory levels. When death does occur, the review found that the quality of autopsies was poor.
Many key comments relate to the use of high doses of opioids – morphine, and diamorphine. “A recurring theme . . . was the excessive doses of opioid analgesics in patients with painful crises. There appeared to be a lack of understanding of the adverse effects of these drugs by doctors and nurses. In addition, assessment of pain, sedation and respiratory rate was infrequently performed.” The report concluded that in nine out of 35 cases of deaths in hospital, excessive doses of opioids had been given. In five cases patients suffered complications as a result “which contributed to the ultimate death of these patients.”
Dr Felix Konotey-Ahulu, clinician and well known expert on sickle cell worldwide, on reading the report commented: “One question that naturally arises is: so what kind of supervision led to this? . .. If the patient dies, sickle cell crisis and chest syndrome will be recorded on the death certificate. No mention is made of the fact that the night nurse on duty was an agency nurse who had not observed until the morning that the patient was hardly breathing from the opiates.” He also pointed out that in his own experience as director of the second largest sickle cell clinic in the world, in Ghana, and in the experience of another known expert Professor Graham Serjeant in Jamaica, treatment with morphia and its derivatives is never deemed necessary. They concentrate on managing the patient, helping them to stay out of hospital as much as possible by avoiding known risk factors, and treating painful crises with established protocols such as fluid intake.
Patient fears drug will kill them - proven
Neville Clare PhD, who is chair of the campaign group Sickle Watch and has campaigned on behalf of sickle cell patients in Britain for over thirty years, says: “For years we have been saying diamorphine – which is heroin – is much more dangerous than the British medical establishment makes out. Here is the confirmation.
“It is not just Ghana and Jamaica, with all their experience of sickle cell, that do not use this drug. In the United States it is never used clinically.” He gives an explanation of the background to the current problems. “In Britain it is a different story. Back in the nineties one patient died from an excessive dose of the previous drug. Suddenly patients here were told they had to change over to diamorphine – no choice. Some of them said they did not want this drug, they did not like what it did to them, they feared it would kill them or they might develop drug dependency or be stigmatised as addicts whether they were or not. The patients were not listened to, they were told it was safe – basically the doctors thought diamorphine was an easy option for themselves. They have believed it is okay for junior nursing staff to give this drug and then ignore the patients, or at least not supervise them closely enough.
“Now everything the patients feared would happen is happening. They are still offered nothing but diamorphine when they are in crisis. Many staff think sickle cell patients are addicts and behave towards them accordingly. And the NHS is giving patients this drug, on the wards, and patients are dying because their breathing gets worse and worse and nobody notices. It is a tragedy and a scandal.”
An article about the report featured in a recent issue of the British Medical Journal, written by Susan Mayor. It quoted David Mason, consultant anaesthetist at the John Radcliffe Hospital, Oxford, and co-author of the enquiry report: “The results highlighted that haemoglobinopathies are complex and complicated diseases. We found a surprisingly high number of cases where we did not know the actual cause of death.” Noting that sickle cell disorder affects every organ of the body, he added, “We need much better information on these patients and their management in order to improve their care.”
The report, A Sickle Crisis? by the National Confidential Enquiry into Patient Outcome and Death, is available at www.ncepod.org.uk.
Correspondence on the issues, on the BMJ website, can be consulted at http://www.bmj.com/cgi/eletters/336/7654/1152-a
--------------------------------------------------------------------------------
E-mail this article to a friend Printable version
--------------------------------------------------------------------------------
If you found this article useful please click here to make a donation
--------------------------------------------------------------------------------
Nigeria sickle-cell deaths 80% African total
Search in this itemKeywordsType of queryAll keywordsOne or more keywordsNone of the keywordsSearchPosted on Friday 29 August 2008 - 09:47
--------------------------------------------------------------------------------
Murtala
Profile131 messages
--------------------------------------------------------------------------------
Murtala Mohamed Kamara, AfricaNews reporter in Freetown, Sierra Leone
The World Health Organization (WHO), said that Nigeria accounts for 75% of infant sickle-cell cases and almost 80% of infant deaths in Africa. The figures released by the WHO state that over 2,000 infants are born with sickle-cell in Africa and Nigeria accounts for 1500 of them.
Mr. Sadiq Wali, president of the Nigerian Sickle-cell Foundation told the Humanitarian Integrated Regional Information Network ( IRIN) that the sickle-cell genetic disorder kills over one thousand children each year.
According WHO of the 2000 children born with the disease 60% will die as infants. An expert says sickle-cell disorder is an incurable disease which is widespread on the continent and African descendants worldwide.
Sufferers have no visible symptoms but periodically experience severe pain and are also highly prone to anemia because the blood cells break down after only 10-20 days, rather than the usual four months.
Sickle-cell anemia is heredity and can be passed from parents to the newly born child. This genetic disorder alone accounts for 8 percent of infant mortality in Nigeria which calls for urgent attention, Wali said.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Reply
SICKLE-CELL KILLING CHILDREN IN NIGERIA
September 6th, 2008 - ANJ Online
Thousands of infants are dying from sickle-cell anemia yearly in Nigeria – one of the highest rates in all Africa, reports the head of the country’s sickle-cell foundation.
"This genetic disorder alone accounts for eight percent of infant mortality in Nigeria, which calls for urgent attention," said foundation head Sadiq Wali.
Meanwhile, Xechem Nigeria will boost production of Nicosan -- used in the treatment of sickle cell disease -- to 50,000 capsules daily in the next six to nine months when a new plant in Abuja, Nigeria, opens. The plant was financed with a two loans, one from the Nigerian Export-Import Bank and another from a U.S. bank.
Xechem International, a New Jersey company, holds exclusive world-wide rights to Nicosan. On July 6, 2006 the drug was officially launched in Nigeria, with the President of Nigeria, Olusegun Obasanjo, in attendance.
According to the World Health Organisation, an average 200,000 infants are born with sickle-cell in Africa, with 150,000 of them found in Nigeria.
Add new comment
Global Health
No Use Of Hydroxyurea In Country With Most Sickle Cell Anemia
December 9, 2007 ⋅ Post a comment
Zakari Aliyu
REFERENCE: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
ZAKARI ALIYU, Howard University, Washington DC
Nigeria has the highest incidence of sickle cell anemia in the world, with over 150,000 children being born each year with the disease. But a new study has shown that no one is using the standard therapy Hydroxyurea to treat it.
Cambridge Who's Who/ - New Brunswick, NJ, April 20, 2008, Dr. Ramesh C. Pandey, Chairman and President of the G. D. Pandey Ayurvedic University (GDPAU), has been recognized by Cambridge Who's Who for showing dedication, leadership and excellence in all aspects of healthcare.
Dr. Pandey has more than 40 years of professional experience in the healthcare industry. He is an expert on drug development and medicinal plant research. Dr. Pandey developed NicosaNTM, a drug for sickle cell anemia, while he was chairman and chief executive officer with Xechem International, Inc. Through GDPAU in collaboration with other institutions, including the University of Toronto Global Health Initiatives, he is working to develop a Traditional Medicine (TM) to treat malaria.
Dr. Pandey earned his post graduate academic degree from the University of Pune, National Chemical Laboratory, Pune in India. He stays current in his profession through research. He is working hard to bring credibility to the Indian system of Ayurvedic medicine, a science of life that treats the body as a whole, and Ayurvedic professions in the Western World. Dr. Pandey intends to set up state-of-the-art facilities in different African countries with the intention of forming an international drug discovery research group, as well as help the economy by creating more job opportunities.
As an expert on medicinal plants, he is available to speak with the media via email at ramesh@gdpau.com.
Drug treatments are still elusive for this disorder, which affects primarily African Americans.
May 5, 2008
By: Kathy Hitchens, Pharm.D., MSBA
Drug Topics
Pages | 1 | 2
Sickle cell disease (SCD) is life-defining. Those with this inherited blood disease never know when a crisis will disrupt their lives. They never know how long SCD is going to interfere with daily living. In many respects SCD determines an individual's quality of life, level of career success, personal finances, and perhaps even longevity—although over the past 30 years improved medical care has significantly improved the lifespan of individuals with SCD.
Progress toward a cure for SCD is moving at an excruciatingly slow pace, hampered by a low public awareness and limited research funding. While some individuals have been cured by bone marrow transplant, for most that is out-of-reach. The only new drug therapy to impact SCD in the last decade is deferasirox (Exjade, Novartis), an iron chelator. Niprisan (Hemoxin, Xechem International, Inc.), a phytopharmaceutical compound approved for treatment of SCD by Nigeria's National Agency for Food & Drug Administration and Control, has caught the interest of many SCD patients. It has not been evaluated by the U.S. Food & Drug Administration, although it has been granted orphan drug status.
SCD afflicts about 80,000 African Americans in the United States. In addition, more than 2.5 million Americans (primarily African Americans) genetically carry the sickle cell trait. SCD is not limited to African Americans; in some parts of the United States a significant number of Hispanic Americans have SCD too.
SCD is not common, but neither is it rare. However, health professionals don't seem to know much about it. Commented Willarda V. Edwards, M.D., MBA, president and COO of the Sickle Cell Disease Association of America (SCDAA), "M.D.s don't know a lot about it."
Sickle cell disease at a glance
That many medical professionals know little about SCD bodes ill for patients who are vulnerable to a variety of disease complications. (See sidebar). "Patients are often isolated, stigmatized, and don't know where to go to obtain the medical care they need," said Allan Platt, PA-C Co-Coordinator, Career Masters Program, Emory University Physician Assistant Program.
ER for SCD patients
To address the needs of SCD patients, "We did something in Atlanta that was unique," Platt said. "We built a specific emergency room (ER) just for them [SCD patients]. They do need ER care. They can have catastrophic complications that present with pain. Atlanta has the only specialized 24-hour center in the world. Some cities have day clinics: New York City and Fort Lauderdale, for example. A couple of cities are trying to start them: Chicago and Memphis haven't gotten funding yet. Otherwise, SCD patients may see a hematologist if they're lucky, or their primary care physician if they can find one who will treat them—and not all hematologists have expertise in SCD."
Without the availability of specialized medical care, SCD patients often wind up in whatever ER that is nearby, in a pain crisis. Platt explained, "Patients with SCD can have chronic pain and then horrible excruciating pain episodes on top of that chronic pain." But because pain is totally subjective, it's hard to convince someone unfamiliar with SCD that the pain is real. But he emphasized, "You've got to believe them."
Platt stated, "We did a study just tracking true addiction in our adult SCD population. During a five-year span, we were the sole provider of treatment in the city. We found the addiction rate to be about 5% in the SCD population, which is way below the incidence in the general public."
Pages | 1 | 2
World News: Sickle Cell Is On The Rise
August 7th, 2008 Sickle cell is on the rise in some communities. Once thought of as a disease that affects only Black Americans, sickle-cell anemia and related blood diseases can also be traced to countries as diverse as Burma, Greece, Saudi Arabia, Spain and the Philippines. Globalization and mixed marriages mean more people are at risk than ever before. Last year, Neighborhood Health Clinics tested 400 Burmese refugees for inherited blood disorders, and another 800 are expected to be tested this year, said Belinda Dean, director of the clinics’ sickle-cell program. About 5 percent have tested positive this year for an inherited disease called hemoglobin E, less serious than sickle cell. “I’ve had people come in here who have a child that tests positive … and they say, ‘There is no way I could be a carrier,’ ” Dean said. “They may not know everything about their ancestry. They may not realize that someone in the family was from Africa or the Mediterranean or Southeast Asia.” About 2 million Americans, including one in 12 Blacks, carry the sickle cell trait, according to the federal National Institutes of Health. For a carrier, there are no or few symptoms, but a child born to two parents with the trait has a one in four chance of developing sickle cell disease. If one parent has the trait and the other doesn’t, all the children will have the trait. If one parent has sickle-cell anemia and the other has the trait, each child born to the couple has a 50 percent chance of having the trait or the disease. Perhaps the silver lining in the increase of people at risk for the trait or the disease is that more funding for sickle-cell research and related diseases could become available. Research using skin stem cells to cure mice with sickle-cell anemia has shown promise, as have bone marrow transplants. Earlier this year, the National Institutes of Health committed to improving and restructuring its sickle-cell research program.
TAGS: cell, Disease, Sickle
Sickle-cell killing children in Nigeria
(GIN)-Thousands of infants are dying from sickle-cell anemia yearly in Nigeria-one of the highest rates in all Africa, reports the head of the country's sickle-cell foundation.
"This genetic disorder alone accounts for eight percent of infant mortality in Nigeria , which calls for urgent attention," said foundation head Sadiq Wali.
Meanwhile, Xechem Nigeria will boost production of Nicosan- used in the treatment of sickle cell disease-to 50,000 capsules daily in the next six to nine months when a new plant in Abuja , Nigeria, opens. The plant was financed with a two loans, one from the Nigerian Export-Import Bank and another from a U.S. bank.
Xechem International, a New Jersey company, holds exclusive world-wide rights to Nicosan. On July 6, 2006 the drug was officially launched in Nigeria, with then-President Olusegun Obasanjo in attendance.
According to the World Health Organization, an average 200,000 infants are born with sickle-cell in Africa, with 150,000 of them found in Nigeria.
Ameritrade shows ask @.001 bid @.0006 is this what y'all have?
Form T = A form required by the NASD for reporting a equity trade executed after normal market hours.
FORM T Does anyone no about this?
MSN Money stock quote shows after hours up 11.11% 4.2 million shares?
Run xkem run!!!!
Agreed, must be more to this spike than a CC, someone knows something...
ditto!!!!
ditto!!!
Ding! .0018
XKEM alive and well, trust me!!!
Ding .002
Xechem US Patents..
1 7,160,910 Anti-sickling agents
2 6,765,015 Halogenated paclitaxel derivatives
3 6,177,456 Monohalocephalomannines having anticancer and antileukemic activity and method of preparation therefor
4 D411,308 Covered multi-well assay plate
5 5,854,278 Preparation of chlorinated paclitaxel analogues and use thereof as antitumor agents
6 5,840,930 Method for production of 2", 3" dihalocephalomannine
7 5,840,748 Dihalocephalomannine and methods of use therefor
8 5,817,510 Device and method for evaluating microorganisms
9 5,807,888 Preparation of brominated paclitaxel analogues and their use as effective antitumor agents
10 5,654,448 Isolation and purification of paclitaxel from organic matter containing paclitaxel, cephalomannine and other related taxanes
11 5,210,226 Method for separating and purifying polyene macrolide antibiotics
12 5,159,002 Method for purifying dermostatin A and dermostatin B
--------------------------------------------------------------------------------
.0039X.004
Fiat..sorry for the confusion...EOM
Settlement after hours up 3.23% 430,000..eom
Old Article...
Health Alert: Sickle cell treatment
Updated: Oct 9, 2007 03:27 PM CDT
Also on the Web
American Sickle Cell Anemia Association
March of Dimes
National Heart, Lung and Blood Institute
Sickle Cell Disease Association of America
The Sickle Cell Information Center
Health more>>
PetSmart stopping bird sales from supplier associated with "parrot fever"
Health Alert: Angioplasty alternative
Many treatment options exist for OCD sufferers
MA men die from contaminated milk
Is There an Advantage in Medicare Alternatives?
High Blood Triglycerides Linked to Stroke Risk
Terriers Join Fight Against a Killer Disease in Humans
Health Alert: Cortical visual impairment
Realistic Expectations Help Ward Off Holiday Depression
What you eat could affect your chances of getting pregnant.
NATIONAL - Sickle cell disease affects millions of people. Researchers know what causes it and how it affects the body, but there's no cure.
Researcher Donald Abraham is excited about a potential new treatment for sickle cell disease. "It's the best thing I have seen in my what, 37 years in this field. It's by far the best. It has the best chance."
"It" is a treatment that could change sickle-shaped blood cells back to normal. Dr. Abraham says, "Anti-sickling will move it back to the donut shape, going from this to the donut shape."
Healthy red blood cells are round and flexible and easily squeezed through blood vessels. In sickle cell disease, the cells are stiff and crescent-shaped. They get stuck and block the flow of oxygen-rich blood to the limbs and organs.
Lucy Brown, 48, says, "Your joints ache, your stomach aches, your back aches, you can ache all over with it."
Brown was born with sickle cell disease. She takes medication to control painful episodes. "If there was something that could stop them completely, that would be a blessing. Yes, it would."
Doctor Abraham's anti-sickling molecule may be the answer to her prayers. "This molecule, 5-HMF, really is a breakdown product in many foods and in plants. So, it's really common in nature."
Researchers at Virginia Commonwealth University say 5-HMF works by attaching itself to red blood cells, increasing their supply of oxygen. Dr. Abraham says, "What you want to do to treat sickle cell is you want to oxygenate this because when it's in the oxygenated red form, it won't sickle."
A drug containing the molecule is in the works. Until then, Lucy remains on pins and needles coping with the pain.
The national Heart, Lung and Blood Institute is funding studies on 5-HMF. It may take years before it's available to patients.
Xechem International has already signed on to market the drug.
Posted by Chantelle Janelle
Ah yes, a famous quote...
Og Mandino wasn't it? "this to shall pass"
Go xkem!!